OncoSynergy Overview
- Year Founded
-
2011

- Status
-
Private
- Employees
-
6

- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$6.16M
- Investors
-
17
OncoSynergy General Information
Description
Developer of novel immunotherapies designed to improve outcomes for cancer patients. The company's immunotherapies employ a transformative strategy based on the resistance mechanism inhibitors principle that inhibits several cancer-driving pathways simultaneously, enabling oncologists to provide durable outcomes and cures for patients.
Contact Information
Website
www.oncosynergy.comCorporate Office
- 850 Pacific Street
- Unit 1802
- Stamford, CT 06902
- United States
Corporate Office
- 850 Pacific Street
- Unit 1802
- Stamford, CT 06902
- United States
OncoSynergy Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
10. Later Stage VC | 13-May-2022 | $6.16M | Completed | Clinical Trials - Phase 1 | ||
9. Later Stage VC | 08-Sep-2020 | Completed | Clinical Trials - Phase 1 | |||
8. Grant | 20-Sep-2019 | Completed | Clinical Trials - General | |||
7. Grant | 01-Jan-2019 | Completed | Clinical Trials - General | |||
6. Later Stage VC (Series A) | 14-May-2018 | Completed | Clinical Trials - General | |||
5. Accelerator/Incubator | 19-May-2017 | Completed | Clinical Trials - General | |||
4. Accelerator/Incubator | Completed | Clinical Trials - General | ||||
3. Merger/Acquisition | 05-Apr-2016 | Cancelled | Clinical Trials - General | |||
2. Equity Crowdfunding | 28-Jun-2015 | $178K | $178K | Completed | Clinical Trials - General | |
1. University Spin-Out | 01-Jan-2011 | Completed | Startup |
OncoSynergy Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A1 | ||||||||
Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
OncoSynergy Comparisons
Industry
Financing
Details
OncoSynergy Competitors (44)
One of OncoSynergy’s 44 competitors is Innovimmune Biotherapeutics, a Accelerator/Incubator Backed company based in New York, NY.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Innovimmune Biotherapeutics | Accelerator/Incubator Backed | New York, NY | ||||
NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
Meditope Biosciences | Venture Capital-Backed | Pasadena, CA | ||||
CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
Centrose | Venture Capital-Backed | Madison, WI |
OncoSynergy Patents
OncoSynergy Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2013370467-A1 | Anti- integrin beta1 antibody compositions and methods of use thereof | Active | 26-Dec-2012 | ||
AU-2013370467-B2 | Anti- integrin beta1 antibody compositions and methods of use thereof | Active | 26-Dec-2012 | ||
AU-2018260887-A1 | Anti- integrin beta1 antibody compositions and methods of use thereof | Inactive | 26-Dec-2012 | ||
EP-2938359-A1 | Anti- integrin beta1 antibody compositions and methods of use thereof | Inactive | 26-Dec-2012 | ||
EP-2938359-A4 | Anti- integrin beta1 antibody compositions and methods of use thereof | Inactive | 26-Dec-2012 | C07K16/2842 |
OncoSynergy Signals
OncoSynergy Investors (17)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
National Cancer Institute | Government | |||
National Institutes of Neurological Disorders and Stroke | Government | |||
Connecticut Innovations | Venture Capital | Minority | ||
Korea Information & Communications | Corporation | Minority | ||
NLabs | Family Office | Minority |
OncoSynergy Acquisitions (1)
OncoSynergy’s most recent deal was a Merger/Acquisition with NexGenix Pharmaceuticals. The deal was made on 01-May-2013.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
NexGenix Pharmaceuticals | 01-May-2013 | Merger/Acquisition | Pharmaceuticals |
OncoSynergy FAQs
-
When was OncoSynergy founded?
OncoSynergy was founded in 2011.
-
Where is OncoSynergy headquartered?
OncoSynergy is headquartered in Stamford, CT.
-
What is the size of OncoSynergy?
OncoSynergy has 6 total employees.
-
What industry is OncoSynergy in?
OncoSynergy’s primary industry is Drug Discovery.
-
Is OncoSynergy a private or public company?
OncoSynergy is a Private company.
-
What is OncoSynergy’s current revenue?
The current revenue for OncoSynergy is
. -
How much funding has OncoSynergy raised over time?
OncoSynergy has raised $29.6M.
-
Who are OncoSynergy’s investors?
National Cancer Institute, National Institutes of Neurological Disorders and Stroke, Connecticut Innovations, Korea Information & Communications, and NLabs are 5 of 17 investors who have invested in OncoSynergy.
-
Who are OncoSynergy’s competitors?
Innovimmune Biotherapeutics, NexImmune, Meditope Biosciences, CytomX Therapeutics, and Centrose are some of the 44 competitors of OncoSynergy.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »